CR

PZ Cormay SAWSE PZ Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Oct, 2024

Last price

Market cap $B

0.011

Micro

Exchange

XWAR - Warsaw Stock Exchange

CRM.WA Stock Analysis

CR

Uncovered

PZ Cormay SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-14/100

Low score

Market cap $B

0.011

Dividend yield

Shares outstanding

84.205 B

PZ Cormay SA engages in the manufacture of diagnostic reagents and laboratory equipment. The company is headquartered in Lomianki, Woj. Mazowieckie and currently employs 218 full-time employees. The company went IPO on 2008-08-20. The firm is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. The company offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.

View Section: Eyestock Rating